In our study, a larger proportion (over 60%) of patients exhibited serum AFP levels <400 ng/mL, suggesting that serum AFP alone cannot be used as a sensitive biomarker for an HCC diagnosis. This evidence concerns the gene AFP and hepatocellular carcinoma.